Q BioMed Inc. has appointed Geoff Fatzinger as Global Head of Regulatory Affairs, responsible for providing strategic regulatory oversight to Q BioMed for product development and commercialization. He will focus on developing the global regulatory approval strategy for the commercialization of Q BioMed’s lead product, the FDA approved, non-opioid Strontium89  (Strontium Chloride Sr-89 Injection, USP). He will also contribute strategic regulatory insight and guidance to the company’s ...